Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients
Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Inflammation of the pancreas (pancreatitis) is an uncommon but potentially serious
complication of endoscopic retrograde cholangiopancreatography (ERCP), a specialized
endoscopic examination of the ducts draining the liver and pancreas. Although many different
strategies have been tried and studied in attempts to reduce this risk, few have been shown
to make a significant difference. Those that have are either very expensive, difficult to
administer, or both.
Diclofenac, an anti-inflammatory medication most often used to treat arthritis, has shown
potential to decrease the risk of post-ERCP pancreatitis. It can be given after the procedure
to patients at most risk for the complication, and has few side effects. This study will
randomize people in the study to placebo or active medication, to determine if Diclofenac
reduces the incidence of pancreatitis.